Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
19.83%
Operating Margin
99.61%
Net Margin
99.61%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
99.61%
Income Tax Rate
0.00%
EPS
3.4500000000
Balance Sheet Analysis
Current Ratio
0.03
Cash Ratio
0.67
Working Capital
$-19.29M
Debt to Equity
0.00
Debt to Assets
0.00%
Equity Ratio
97.77%
Cash Flow Analysis
Operating Cash Flow Ratio
-7.11%
Free Cash Flow Ratio
-7.11%
CapEx to Revenue
0.00%
Dividends Paid
$54.52M
Stock Buybacks
No buybacks
Total Shareholder Returns
$54.52M
Cash Position Change
-133,016,600.0%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
241.99%
Net Income
240.78%
EPS
240.82%
Operating Income
240.77%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-1.11%
Operating Cash Flow
-39.55%
Free Cash Flow
-39.55%
Balance Sheet Health
Assets
13.87%
Debt
-100.00%
Book Value per Share
12.84%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-39.84%
Shares Outstanding
0.03%
Long Term Trends
3Y Revenue/Share
55.67%
5Y Revenue/Share
480.60%
3Y Dividend/Share
17.68%
5Y Dividend/Share
23.91%